221 related articles for article (PubMed ID: 20112006)
1. [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].
Husseini L; Leussink VI; Kieseier BC; Hartung HP
Nervenarzt; 2010 Feb; 81(2):203-11. PubMed ID: 20112006
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T
CNS Neurosci Ther; 2013 May; 19(5):302-6. PubMed ID: 23607697
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
5. [Aminopyridines for symptomatic treatment of multiple sclerosis].
Jensen HB; Stenager E; Ravnborg MH
Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fampridine for walking disability in multiple sclerosis.
Arpín EC
Neurodegener Dis Manag; 2020 Oct; 10(5):277-287. PubMed ID: 32762492
[TBL] [Abstract][Full Text] [Related]
7. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
Jensen HB; Nielsen JL; Ravnborg M; Dalgas U; Aagaard P; Stenager E
Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the efficacy and safety of fampridine.
Mejuto B; Castellano P; Castro C; López LM
Farm Hosp; 2017 Mar; 41(2):283-291. PubMed ID: 28236802
[TBL] [Abstract][Full Text] [Related]
9. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
Mathiesen HK; Sorensen PS
Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
[TBL] [Abstract][Full Text] [Related]
10. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
Fernandez O; Berger T; Hartung HP; Putzki N
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
[TBL] [Abstract][Full Text] [Related]
11. Fampridine-SR for multiple sclerosis and spinal cord injury.
Hayes KC
Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
[TBL] [Abstract][Full Text] [Related]
12. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release fampridine for multiple sclerosis.
Bever CT; Judge SI
Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
15. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
[TBL] [Abstract][Full Text] [Related]
16. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
17. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Keune PM; Cocks AJ; Young WR; Burschka JM; Hansen S; Hofstadt-van Oy U; Oschmann P; Muenssinger J
BMC Neurol; 2015 Sep; 15():171. PubMed ID: 26400041
[TBL] [Abstract][Full Text] [Related]
18. Dalfampridine in multiple sclerosis.
Goodman AD; Hyland M
Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
[TBL] [Abstract][Full Text] [Related]
19. Dalfampridine (Ampyra) for MS.
Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716
[No Abstract] [Full Text] [Related]
20. Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.
Valet M; Quoilin M; Lejeune T; Stoquart G; Van Pesch V; El Sankari S; Detrembleur C; Warlop T
CNS Drugs; 2019 Nov; 33(11):1087-1099. PubMed ID: 31612418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
